Based on the studies, the effects of DSIP (delta sleep-inducing peptide) appear to be relatively rapid. In a study where DSIP was administered to human volunteers, it was reported that after receiving DSIP via slow intravenous infusion at a dosage of 25 nmol/kg in the morning, the subjects immediately reported a feeling of sleep pressure. Furthermore, within a 130-minute interval after the treatment, sleep reportedly increased by 59% compared to a placebo.
In another study involving chronic insomniac patients, DSIP was administered intravenously for four nights, and the results indicated that DSIP treatment decreased the number of nocturnal awakenings, reduced non-rapid-eye-movement (NREM) sleep latency, and decreased total waking time and waking time after sleep onset. Additionally, DSIP increased total sleep time and NREM sleep time, with the increase being related to an increase in stage 2 sleep.
These findings suggest that DSIP may have relatively rapid effects on sleep behavior, including promoting a feeling of sleep pressure shortly after administration and positively impacting sleep parameters within a few nights of treatment. However, individual responses to DSIP may vary, and further research may provide additional insights into the timing and duration of its effects.
